35 Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study

Szerző: Constantine S. Tam, MBBS, MD¹ Tanya Siddiqi, MD² John N. Allan, MD³ Thomas J. Kipps, MD, PhD⁴ Ian W. Flinn, MD, PhD⁵ Bryone J. Kuss, MBBS, PhD, FRACP, FRCPA⁶ Stephen Opat, FRACP, FRCPA, MBBS⁷ Paul M. Barr, MD⁸ Alessandra Tedeschi, MD⁹ Ryan Jacobs, MD¹⁰ Xavier C. Badoux, MBBS, FRACP, FRCPA¹¹ Paolo Ghia, MD, PhD¹² Juthamas Sukbuntherng, PhD¹³ Ahmed Hamed Salem, PhD, FCP¹⁴ Kristin Russell, BS¹⁵ Karl Eckert, BA¹⁶ Cathy Zhou, MS¹⁷ Joi Ninomoto, PharmD¹⁸ Danelle F. James, MD, MAS¹⁹ William G. Wierda, MD, PhD²⁰
¹St. Vincent's Hospital and University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia
²City of Hope National Medical Center, Duarte, CA
³Weill Cornell Medicine, Long Island City, NY
⁴UCSD Moores Cancer Center, San Diego, CA
⁵Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
⁶Flinders Medical Centre, Bedford Park, Australia
⁷Monash University, Clayton, VIC, Australia
⁸Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
⁹ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
¹⁰Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC
¹¹Ministry of Health, St George Hospital, Kogarah, Australia
¹²Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
¹³Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹⁴AbbVie, North Chicago, IL
¹⁵Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹⁶Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹⁷Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹⁸Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹⁹Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
²⁰University of Texas M.D. Anderson Cancer Center, Houston, TX

Background: Ibr is the only once-daily inhibitor of Bruton tyrosine kinase with significant overall survival benefit demonstrated in 2 randomized phase 3 studies in first-line CLL (RESONATE-2; ECOG1912). Both Ibr and Ven, an oral inhibitor of BCL2, are approved in the US for treatment of CLL/SLL. The combination of Ibr + Ven may have synergistic anti-tumor activity given the capacity of Ibr to mobilize CLL cells from protected niches within ...

3054 Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Szerző: Paul M. Barr, MD¹ Alessandra Tedeschi, MD² Talha Munir, MD³ Peter Hillmen, MD, PhD⁴ John C Byrd, MD⁵ Paolo Ghia, MD, PhD⁶ Stephen Mulligan, MBBS, MD, FRACP, FRCPA⁷ Sandra Dai, PhD, MS⁸ Carlos Amaya-Chanaga, MD⁹ James P. Dean, MD, PhD¹⁰ Susan M. o'Brien, MD¹¹
¹Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY
²Department of Haematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
³Department of Haematology, Leeds Teaching Hospitals, Leeds, United Kingdom
⁴The Leeds Teaching Hospitals, St. James University Hospital, (Leeds Cancer Centre, St. James' Institute of Oncology), Leeds, United Kingdom
⁵The Ohio State University, Columbus, OH; Comprehensive Cancer Center, The Ohio State University, Columbus, OH
⁶Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
⁷Royal North Shore Hospital, Sydney, AUS
⁸Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
⁹Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹⁰Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
¹¹UC Irvine, Chao Family Comprehensive Cancer Center, Orange, CA

Background: Ibrutinib is the only once-daily Bruton’s tyrosine kinase inhibitor with significant progression-free survival (PFS) benefit demonstrated in 5 randomized phase 3 studies in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) compared with standard-of-care chemotherapy and/or immunotherapy (RESONATE, RESONATE-2, iLLUMINATE, Alliance 041202, and ECOG 1912), and significant overall survival (OS) benefit in 3...

33 Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Szerző: Tait D. Shanafelt, MD¹ Victoria Wang² Neil E. Kay, MD³ Curtis A. Hanson, MD⁴ Susan M. O'Brien, MD⁵ Jacqueline C. Barrientos, MD, MS⁶ Diane F Jelinek, PhD⁷ Esteban Braggio, Ph.D.⁸ Jose F. Leis, MD, PhD⁹ Cong Christine Zhang¹⁰ Steven Coutre, MD¹¹ Paul M. Barr, MD¹² Amanda F Cashen, MD¹³ Anthony R. Mato, MD MSCE¹⁴ Avina Singh, MD¹⁵ Michael P. Mullane, MD¹⁶ Richard F. Little, MD, MPH¹⁷ Harry P. Erba, MD, PhD¹⁸ Richard M. Stone, MD¹⁹ Mark Litzow, MD²⁰ Martin S. Tallman, MD²¹
¹Stanford University, Stanford, CA
²Harvard, Boston, MA
³Division of Hematology, Mayo Clinic, Rochester, MN
⁴Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
⁵Chao Family Comprehensive Cancer Center, Division of Hematology / Oncology, Department of Medicine, University of California Irvine Health, Orange, CA
⁶Department of Medicine, Zucker School of Medicine at Hofstra/Northwell, Lake Success, NY
⁷College of Medicine, Mayo Clinic, Scottsdale, AZ
⁸Division of Hematology/Oncology, Mayo Clinic, Scottsdale, AZ
⁹Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ
¹⁰Kaiser Permanente, Fresno, CA
¹¹Stanford Univ. School of Med., Stanford, CA
¹²Division of Hematology/Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, NY
¹³Department of Medicine, Washington Univ. School of Med., Saint Louis, MO
¹⁴Center for CLL, Memorial Sloan-Kettering Cancer Center, New York, NY; CLL Program, Leukemia Service, Hematologic Malignancies Division, Memorial Sloan Kettering Cancer Center, New York, NY
¹⁵Minnesota Oncology, Burnsville, MN
¹⁶Aurora Cancer Care-Racine, Racine, WI
¹⁷National Cancer Institute, Washington; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; National Institutes of Health National Cancer Institute, Bethesda, MD
¹⁸University of Alabama at Birmingham, Birmingham, AL
¹⁹Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
²⁰Division of Hematology, Mayo Clinic, Rochester, MN
²¹Memorial Sloan Kettering Cancer Center, New York, NY

BACKGROUND:Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) has been the standard therapy for younger patients with CLL. FCR therapy is particularly effective in patients with immunoglobulin heavy chain variable region (IGHV) mutated CLL. Approximately half of IGHV mutated patients are progression free 8 years after FCR therapy. At the ASH 2018 meeting, we reported the initial results of the ECOG 1912 (E1912) trial, a ...